Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Voyager Therapeutics, Inc. (Nasdaq: VYGR) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures, including current reports on Form 8-K that furnish financial results, corporate updates, and investor presentations. As a Delaware-incorporated public company with common stock listed on the Nasdaq Global Select Market, Voyager files with the U.S. Securities and Exchange Commission to report material information related to its biotechnology business focused on neurological diseases.
Through these filings, readers can access details on Voyager’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities. The company’s 8-K filings often attach press releases that describe quarterly financial and operating results, cash runway expectations, and progress across its pipeline, including Alzheimer’s disease programs such as the anti-tau antibody VY7523 and tau silencing gene therapy VY1706, as well as partnered gene therapy programs with Neurocrine Biosciences and collaborations with Novartis and other partners.
Voyager’s filings also reference its TRACER™ AAV capsid discovery platform, next-generation capsids designed for blood-brain barrier penetration, and collaborations such as the small molecule discovery and license option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia. Forward-looking statements and risk disclosures in these documents outline uncertainties related to regulatory decisions, clinical development, collaboration milestones, intellectual property, and the company’s ability to fund operations.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major financial metrics, pipeline updates, and collaboration terms. Users can follow new 8-Ks and other SEC reports in real time, review historical filings for context on Voyager’s evolution, and connect these disclosures to the company’s news flow and stock performance.
Voyager Therapeutics, Inc. Chief Financial Officer Nathan D. Jorgensen reported an open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. After this non-discretionary sell-to-cover tax transaction, he holds 151,416 shares directly.
Voyager Therapeutics’ Chief Scientific Officer, Carter Todd Alfred, reported an automatic sale of 4,174 shares of common stock at a weighted average price of $3.76 per share.
The shares were sold under a pre-set instruction to cover tax withholding tied to restricted stock units vesting on February 21, 2026, and he continues to hold 145,718 shares directly.
Notice of proposed resale under Rule 144 by a holder associated with restricted stock vesting. The filing lists a planned sale of 4,174 common shares tied to restricted stock vesting on 02/20/2026. It also reports two completed dispositions in the prior three months: 3,525 shares on 02/10/2026 and 3,301 shares on 02/18/2026, each attributed to Todd Carter. Fidelity Brokerage Services LLC is shown as the broker.
VYGR reports a planned sale of 6,458 common shares under Rule 144 tied to restricted stock vesting on 02/20/2026.
The filing also discloses prior dispositions by Robin E. Swartz in the past three months: 4,569 shares sold on 02/10/2026 for $17,598.87 and 3,882 shares sold on 02/18/2026 for $13,349.03. The planned sale is labeled as Issuer and linked to Compensation (restricted stock vesting).
VYGR reports a restricted stock vesting of 14,197 common shares effective 02/20/2026.
The filing also discloses recent open‑market dispositions by Alfred W. Sandrock Jr.: 12,192 shares sold on 02/10/2026 for $46,093.08 and 11,732 shares sold on 02/18/2026 for $40,038.97.
Voyager Therapeutics, Inc. executive Robin Swartz, the company’s COO & CBO, reported an open-market sale of 3,882 shares of common stock at a weighted average price of $3.44 per share on February 18, 2026. The sale was made under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations tied to restricted stock units that vested on February 17, 2026, and is described as non-discretionary. Following this transaction, Swartz directly owned 206,196 common shares of Voyager Therapeutics.
Voyager Therapeutics, Inc. Chief Scientific Officer Carter Todd Alfred reported an automatic open-market sale of 3,301 shares of common stock at a weighted average price of $3.44 per share. The shares were sold under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and are described as not being a discretionary trade. Following this transaction, Alfred directly holds 149,892 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,732 shares of common stock of Voyager Therapeutics at a weighted average price of $3.41 per share. According to the disclosure, this transaction was executed under a durable automatic sale instruction adopted on May 12, 2025.
The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and the filing states that the sale did not represent a discretionary trade by the reporting person. After this tax-related sale, Sandrock directly holds 498,257 shares of Voyager Therapeutics common stock.
Voyager Digital affiliate reported transactions of Common stock in a Form 144 notice. The filing shows a sale of 12,192 shares on 02/10/2026 with proceeds of $46,093.08. The notice also lists 11,732 shares tied to restricted stock vesting dated 02/17/2026.